Epcoritamab

Phase 3

GENMAB A/S (GNMSF)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jun '27

GNMSFPhase 3$21.5B

Epcoritamab Phase 3 Est. Readout

Epcoritamab• DLBCL900

Jun 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in DLBCL

View Full Landscape

Drug Information

Target Indication

DLBCL

Clinical Trial

NCT03625037

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA9/22/2023

Tepkinly

Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Tepkinly in combination with lenalidomide and rituximab is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Conditional

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

GNMSF

GENMAB A/S

Biotechnology•North America•NASDAQ

Related Pipeline

ZalutumumabPhase 3

Head and Neck Neoplasms

Rina-SPhase 3